Citius Pharmaceuticals
CTXR
74 hedge funds and large institutions have $20.3M invested in Citius Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 12 closing their positions.
284% more capital inflows, than outflows
Capital inflows: $2.16M | Capital outflows: $561K
105% more call options, than puts
Call options by funds: $90K | Put options by funds: $44K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
1.18% more ownership
Funds ownership: 15.7% → 16.88% (+1.2%)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding
Funds holding: 74 → 74 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$652K |
| 2 |
BlackRock
New York
|
+$510K |
| 3 |
Morgan Stanley
New York
|
+$127K |
| 4 |
Barclays
London,
United Kingdom
|
+$112K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$79.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
-$136K |
| 2 |
Wealth Advisory Solutions
Indiianapolis,
Indiana
|
-$105K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$76.3K |
| 4 |
Renaissance Technologies
New York
|
-$61K |
| 5 |
Goldman Sachs
New York
|
-$46.8K |
CTXR Hedge Fund Activity: Q4 2023 in Review
74 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2023, worth a combined $20.3M — up 19% from $17.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CTXR positions and 12 closed out — a net gain of 1 holder — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $652K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $136K sold.
- 74 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $20.3M of Citius Pharmaceuticals stock for Q4 2023, up 19% quarter-over-quarter.
- 13 funds opened new Citius Pharmaceuticals positions in Q4 2023 and 12 closed out, a net change of +1 holder.
- The largest Citius Pharmaceuticals buyer in Q4 2023 was Osaic Holdings, an estimated $652K added.
- The largest Citius Pharmaceuticals seller in Q4 2023 was GSA Capital Partners, an estimated $136K sold.
Based on aggregated 13F filings for Q4 2023.